EUVIMEDEUVIMED entdecken
Open Access

The SeqSplice multiplexed minigene splicing assay for characterization and quantitation of variant-induced BRCA1 and BRCA2 splice isoforms

Daffodil M Canson iD, Michael T Parsons iD, Gemma Moir-Meyer, Troy Dumenil, Gemma Montalban, Erica Lin, Terri P McVeigh, Aimee L Davidson, Shaun M Bouckaert, Matt Trau, Darren Korbie, Amanda B Spurdle

Genome Research · 2025

DOI: 10.1101/gr.279557.124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genome Research, 2025. Verfasst von Daffodil M Canson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Population Health Program, QIMR Berghofer, Herston, Queensland 4006, Australia. Hauptthemen laut MEDLINE: BRCA2 Protein, BRCA1 Protein, Alternative Splicing, RNA Splicing. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Health and Medical Research Council, National Institutes of Health, Fundació Montcelimar—Universitat de Barcelona.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BRCA1 and BRCA2 germline variant classification is vital for clinical management of families with hereditary breast and ovarian cancer. However, clinical classification of rare variants outside of the splice donor/acceptor ±1,2-dinucleotides remains challenging, particularly for variants that induce new or cryptic splice site usage. Here, we present SeqSplice , a high-throughput RNA splicing methodology utilizing barcoded minigene constructs together with a bespoke bioinformatics pipeline for identifying and quantifying the impacts for splice-altering variants. SeqSplice exhibits excellent reproducibility across cDNA input and PCR cycle differences and is able to identify and quantitate transcripts that differed by a single base. Of the 193 BRCA1 and 72 BRCA2 variants profiled, 89% (237/265) had no publicly available RNA splicing data. Complete or near complete impact owing to splice site gain/loss is observed for 42 variants, with 30 (71%) producing alternative transcripts owing to new or cryptic splice sites. These findings are used to update our aberration type predictor called SpliceAI-10k calculator, resulting in 94% specificity and 90% sensitivity for major alternative transcripts (>50% proportion). Comparison of SeqSplice findings for 28 variants with published data shows the value and limitations of using construct-based results for variant classification. Overall, our findings inform use of construct-derived data for clinical variant classification. We show that construct-derived results for variants showing low or no splicing impact provide reliable evidence against variant pathogenicity, whereas—for variants demonstrating splicing impact—construct design and naturally occurring alternative splicing are important considerations for assigning and weighting evidence towards pathogenicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BRCA2 ProteinBRCA1 ProteinAlternative SplicingRNA SplicingHumansProtein IsoformsFemaleRNA Splice SitesReproducibility of ResultsBreast NeoplasmsOvarian Neoplasms

Substanzen

BRCA2 ProteinBRCA1 ProteinBRCA2 protein, humanBRCA1 protein, humanProtein IsoformsRNA Splice Sites

Autor:innen und Institutionen

  • Population Health Program, QIMR Berghofer, Herston, Queensland 4006, Australia.
  • Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia.
  • Department of Medical Biology, The University of Melbourne, Parkville, Victoria 3010, Australia.
  • Cancer Research Program, QIMR Berghofer, Herston, Queensland 4006, Australia.
  • Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Cellex Center, 08035 Barcelona, Spain.
  • Department of Oncogenetics, MRC Holland, 1057 DL Amsterdam, The Netherlands.

ORCID-Profile: Daffodil M Canson, Michael T Parsons

Förderung

  • National Health and Medical Research Council
  • National Institutes of Health
  • Fundació Montcelimar—Universitat de Barcelona
  • National Breast Cancer Foundation
  • National Breast Cancer Foundation Research Fellow

Zitieren

APA

Canson, D. M., Parsons, M. T., Moir-Meyer, G., Dumenil, T., Montalban, G., Lin, E., McVeigh, T. P., Davidson, A. L., Bouckaert, S. M., Trau, M., Korbie, D., & Spurdle, A. B. (2025). The SeqSplice multiplexed minigene splicing assay for characterization and quantitation of variant-induced BRCA1 and BRCA2 splice isoforms. Genome Research. https://doi.org/10.1101/gr.279557.124

Vancouver

Canson DM, Parsons MT, Moir-Meyer G, Dumenil T, Montalban G, Lin E, et al. The SeqSplice multiplexed minigene splicing assay for characterization and quantitation of variant-induced BRCA1 and BRCA2 splice isoforms. Genome Research. 2025. doi:10.1101/gr.279557.124

BibTeX
@article{Canson2025,
  author = {Canson, Daffodil M and Parsons, Michael T and Moir-Meyer, Gemma and Dumenil, Troy and Montalban, Gemma and Lin, Erica and McVeigh, Terri P and Davidson, Aimee L and Bouckaert, Shaun M and Trau, Matt and Korbie, Darren and Spurdle, Amanda B},
  title = {The SeqSplice multiplexed minigene splicing assay for characterization and quantitation of variant-induced BRCA1 and BRCA2 splice isoforms},
  journal = {Genome Research},
  year = {2025},
  doi = {10.1101/gr.279557.124}
}
Kostenlos starten →